Tissue polypeptide-specific antigen (TPS) determinations before and during intermittent maximal androgen blockade in patients with metastatic prostatic carcinoma

European Urology

Volumn 43, Issue 1, 2003, Pages 31-38

  Kil, P J M ^a   Goldschmidt, H M J ^a   Wieggers, B J A ^a   Kariakine, O B ^b   Studer, U E ^c   Whelan, P ^h   Hetherington, J ^d   Th M de Reijke, ^e   Hoekstra, J W ^f   Collette, L ^g  

^a CPRLab   (Netherlands)

^b MEDICAL RADIOLOGICAL RESEARCH CENTER   (Russian Federation)

^c UNIVERSITY OF BERN   (Switzerland)

^d PRINCESS ROYAL HOSPITAL   (United Kingdom)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f JEROEN BOSCH HOSPITAL   (Netherlands)

^g EORTC DATA CENTER   (Belgium)

^h NONE

Author keywords

Intermittent maximal androgen blockade; Prognostic value; Prostate cancer; Tumor markers

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; GOSERELIN; PROSTATE SPECIFIC ANTIGEN; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

ANTIGEN DETECTION; ARTICLE; CANCER GROWTH; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROSTATE METASTASIS; TREATMENT OUTCOME;

EID: 12244286056     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(02)00499-2     Document Type: Article

References (24)

1. Csapo Z, Brand K, Walther R, Tokas K. Comparative experimental study of the serum prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice. J Urol 1988;140:1032-8.
2. Leo ME, Bilhartz DL, Bergstralh EJ, Oesterling JE. Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status? J Urol 1991;145:802-6.
3. Miller JI, Ahmann FR, Drach GW, Emerson SS, Bertacini MR. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 1992;147:956-61.
4. Dupont A, Cusan L, Gomez JL, Thibeault MM, Tremblay M, Labrie F. Prostate specific antigen and prostatic acid phosphatase for monitoring therapy of carcinoma of the prostate. J Urol 1991;146:1064-8.
5. Bruchovsky N, Brown EM, Coppin CM, Goldenberg SL, Le Riche JC, Murray NC, et al. The endocrinology and treatment of prostate tumor progression. Prog Clin Biol Res 1987;239:347-87.
6. Sella A, Konichezky M, Flex D, Sulkes A, Baniel J. Low PSA metastatic androgen-independent prostate cancer. Eur Urol 2000;38:250-4.
7. Weber JP, Oesterling JE, Peters CA, Partin AW, Chan DW, Walsh PC. The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia. J Urol 1989;141:987-92.
8. Mulders PF, Dijkman GA, Fernandez del Moral P, Theeuwes AGM, Debruyne FMJ. Analysis of prognostic factors in disseminated prostatic cancer: an update. Cancer 1990;65:2758-61.
9. Matzkin H, Perito PE, Soloway MS. Prognostic factors in metastatic prostate cancer. Cancer 1993;72(Suppl):3788-92.
10. Stokkel M, Zwinderman A, Zwartendijk J, Pauwels E, van Eck-Smit B. The value of pretreatment clinical and biochemical parameters in patients with newly diagnosed untreated prostate carcinoma and no indications for bone metastases on the bone scintigram. Eur J Nucl Med 1997;24:1215-20.
11. Kawakami S, Takagi K, Yonese J, Ueda T, Fukui I, Kawai T. Prognostic significance of prostate-specific antigen levels two months after hormonal manipulation of metastatic prostate cancer. Eur Urol 1997;32:58-63.
12. Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993;11:607-15.
13. Zagars GK, Sands ME, Pollack A, von Eschenbach AC. Early androgen ablation for stage D1 (N1 to N3, MO) prostate cancer: prognostic variables and outcome. J Urol 1994;151:1330-5.
14. Bjorklund B, Bjorklund V, Brunkener M, Gronlund H, Bach M. The enigma of a human tumor marker: TPA revisited. In: Ciminio F, Birkmayer GD, Klavius JV, Pimentel E, Salvatore F, editors. Human tumor markers. Berlin: Walter de Gruyter; 1987. p. 169-80.
15. Tarle M, Erkovic-Grazio S, Kraljic I, Kovacic K. A more objective staging of advanced prostate cancer routine recognition of malignant endocrine structures: the assessment of serum TPS, PSA and NSE values. Prostate 1994;24:143-8.
16. Polito M, Minardi D, Recchioni A, Giannulis I, De Sio G, Muzzonigro G. Serum markers for monitoring of prostatic carcinoma. Prostate 1997;33:208-16.
17. Kramer G, Steiner GE, Madersbacher S, Stulnig T, Lang T, Marberger M. Serial tissue polypeptide specific antigen determinations in the followup of hormone treated carcinoma of the prostate. J Urol 1997;158:1446-51.
18. Tarle M. Serial measurements of Tissue Polypeptide Specific Antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer. Anticancer Res 1993;13:769-78.
19. Theyer G, Holub S, Durer A, Andert S, Haberl I, Theyer U, et al. Measurement of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy. Br J Cancer 1997;75:1515-8.
20. Albrecht W, Koriakine OB, Whelan P, Studer UE, de Reijke TM, Fava C, et al. Intermittent maximal androgen blockade in patients with metastatic prostate cancer - a feasibility study. Eur Urol 2000;37(Suppl 2):127.
21. Ceriani L, Giovanella L, Salvadore M, Bono AV, Roncari G. Tissue polypeptide-specific antigen (TPS) immunoassay in the diagnosis and clinical staging of prostatic carcinoma. Comparison with prostate-specific antigen (PSA). Int J Biol Markers 1997;12:27-34.
22. Marrink J, Oosterom R, Bonfrer HMG, Schroder FH, Mensink HJA. Tissue Polypeptide specific Antigen: a discriminative parameter between prostate cancer and benign prostatic hypertrophy. Eur J Cancer 1993;29A:570.
23. Theyer G, Durer A, Theyer U, Haberl I, Ulsperger E, Baumgartner G. Measurement of free and total PSA, tissue polypeptide-specific antigen (TPS) ans CYFRA 21-1 in prostate cancer patients under intermittent androgen suppression therapy. Prostate 1999;41:71-7.
24. Wolff JM, Borchers H, Brehmer B, Brauers A, Jakse G. Cytokeratin markers in patients with prostatic diseases. Antincancer Res 1999;19:2649-52.